ALSO READNot overcharged patients for stents: Max Healthcare New low-cost method may provide hope for leukemia patients Geelani criticises UN Secy General for not mentioning Kashmir SC refuses to give guidelines banning Sardar jokes, to issue detailed order on March 27 PM justifies note ban, but skips mentioning deaths (Roundup)
National Pharmaceuticals Pricing Authority (NPPA) has directed hospitals to issue detailed bills to the patients, specifically and separately mentioning the cost of the coronary stents, along with the brand name of the manufacturer and importer, batch number and other details, said Minister of State for Chemical and Fertilisers Mansukh Mandaviya on Tuesday.
In a written reply to Lok Sabha, Mandaviya also said that non-compliance thereof will be treated as deliberate distortion of evidence along with charges of overpricing inviting prosecution under the Essential Commodities Act.
"Through NPPA, is closely monitoring the situation and has alerted the State Governments and State Drugs Controllers to monitor the availability of stents. Industry has also been apprised that all manufactures and importers are under legal obligation to maintain smooth production and supply of coronary stents of all brands which were available in the country before price cap," said Mandaviya.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)